LYSP Stock Overview

Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. More details

LYSP fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Negative shareholders equity

Shares are highly illiquid

Shareholders have been diluted in the past year

Does not have a meaningful market cap (€11M)

My Notes

Capture your thoughts, links and company narrative

Lysogene S.A. Competitors

ProBiotix Health

OFEX:PBX

UK£9.1m

Verici Dx

AIM:VRCI

UK£6.4m

Genflow Biosciences

LSE:GENF

UK£5.4m

Aptamer Group

AIM:APTA

UK£6.9m

Price History & Performance

Summary of share price highs, lows and changes for Lysogene
Historical stock prices
Current Share Price	€0.81
52 Week High	€2.06
52 Week Low	€0.81
Beta	0.68
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-78.86%

Recent updates

Shareholder Returns

	LYSP	GB Biotechs	GB Market
7D	0%	-4.4%	-2.6%
1Y	n/a	-22.3%	2.7%

Return vs Industry: Insufficient data to determine how LYSP performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how LYSP performed against the UK Market.

Price Volatility

Is LYSP's price volatile compared to industry and market?
LYSP volatility
LYSP Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.5%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: LYSP has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine LYSP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	21	Karen Pignet-Aiach	www.lysogene.com

Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases.

Lysogene S.A. Fundamentals Summary

How do Lysogene's earnings and revenue compare to its market cap?
LYSP fundamental statistics
Market cap	€11.40m
Earnings (TTM)	-€13.61m
Revenue (TTM)	€6.95m

1.6x

P/S Ratio

-0.8x

P/E Ratio

Is LYSP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LYSP income statement (TTM)
Revenue	€6.95m
Cost of Revenue	€0
Gross Profit	€6.95m
Other Expenses	€20.56m
Earnings	-€13.61m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.79
Gross Margin	100.00%
Net Profit Margin	-195.81%
Debt/Equity Ratio	-200.2%

How did LYSP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/07/04 12:51
End of Day Share Price	2022/04/06 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lysogene S.A. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eric Le Berrigaud	Bryan Garnier & Co
Lea De Cabezon	Gilbert Dupont
Delphine Le Louet	Societe Generale Cross Asset Research